Drug intelligence / Profile preview

ADC0320

Development stage: Unknown
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ADC0320 is an antibody-drug conjugate (ADC) targeting Tissue Factor (TF), a transmembrane glycoprotein involved in the extrinsic coagulation pathway that is frequently overexpressed in solid tumors. Developed by Protheragen, ADC0320 is designed to selectively deliver a cytotoxic agent to TF-expressing malignant cells, thereby inducing cell death while sparing healthy tissues with low TF expression. The program is currently in Phase I clinical development for the treatment of various cancers.

Targets

F3 (Tissue factor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ADC0320.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC0320.

Explore the full profile